Trade DNLI stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Denali Therapeutics Inc. (DNLI) is trading at US$20.96, up 7.76% today as of Nov 4, 16:00 EST. The company has a market capitalisation of US$3.98B. Over the past 52 weeks, DNLI has traded between US$13.75 and US$27.30. On Syfe you can trade DNLI with $0 commission and add it to your watchlist.
| Previous close | US$19.45 |
|---|---|
| Market cap | US$3.98B |
| 52-week range | US$13.75 – US$27.30 |
| Volume | 4.65M |
| Exchange | US |
Denali Therapeutics Inc.
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Year: 2017
Denali Therapeutics Inc. (DNLI) stock is trading at US$20.96, +7.76% from the previous close of US$19.45.
The market cap for Denali Therapeutics Inc. (DNLI) stock is approximately US$3.98B.
The 52-week high for Denali Therapeutics Inc. (DNLI) stock is US$27.30.
The 52-week low for Denali Therapeutics Inc. (DNLI) stock is US$13.75.
Denali Therapeutics Inc. (DNLI) does not currently pay a dividend.
Stay on top of DNLI
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore
